CR8224A - Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor - Google Patents
Polipepticos cristalinos del receptor 2 del factor de necrosis de tumorInfo
- Publication number
- CR8224A CR8224A CR8224A CR8224A CR8224A CR 8224 A CR8224 A CR 8224A CR 8224 A CR8224 A CR 8224A CR 8224 A CR8224 A CR 8224A CR 8224 A CR8224 A CR 8224A
- Authority
- CR
- Costa Rica
- Prior art keywords
- crystal
- polipeptices
- necrosis factor
- tumor necrosis
- factor receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invencion suministra formas cristalinas de los polipeptidos TNFR2, que incluyen los polipeptidos TNFR2:Fc y el etanercept cristalino. Una modalidad de la invencion es un cristal de etanercept; en ciertas modalidades el cristal de etanercept esta en la forma de una barra, y /o tiene una longitud maxima de entre 0.5 milimetros y 1.5 milimetros de entre 0.05 milimetros y 0.3 milimetros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49182703P | 2003-08-01 | 2003-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR8224A true CR8224A (es) | 2006-07-18 |
Family
ID=34115556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR8224A CR8224A (es) | 2003-08-01 | 2006-02-01 | Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor |
Country Status (19)
Country | Link |
---|---|
US (1) | US7276477B2 (es) |
EP (1) | EP1654281A1 (es) |
JP (1) | JP2007521315A (es) |
KR (1) | KR20070008501A (es) |
CN (1) | CN100509847C (es) |
AU (1) | AU2004262014B2 (es) |
BR (1) | BRPI0413197A (es) |
CA (1) | CA2533796A1 (es) |
CR (1) | CR8224A (es) |
EC (1) | ECSP066299A (es) |
HK (1) | HK1093749A1 (es) |
IL (1) | IL173413A0 (es) |
NO (1) | NO20060128L (es) |
NZ (1) | NZ545221A (es) |
RU (1) | RU2006101216A (es) |
SG (1) | SG145712A1 (es) |
TW (1) | TWI291468B (es) |
WO (1) | WO2005012353A1 (es) |
ZA (1) | ZA200600909B (es) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9549895B2 (en) * | 2004-04-23 | 2017-01-24 | Massachusetts Eye And Ear Infirmary | Methods and compositions for preserving the viability of photoreceptor cells |
US20060046960A1 (en) * | 2004-09-02 | 2006-03-02 | Mckay William F | Controlled and directed local delivery of anti-inflammatory compositions |
US20090232808A1 (en) * | 2005-01-28 | 2009-09-17 | Apollo Life Sciences Limited | Molecules and chimeric molecules thereof |
CN1954882A (zh) * | 2005-10-14 | 2007-05-02 | 李海 | 长效人重组可溶性肿瘤坏死因子α受体在制备防治肝衰竭药物中的用途 |
CA2629323A1 (en) * | 2005-11-10 | 2007-05-24 | The University Of North Carolina At Chapel Hill | Splice switching oligomers for tnf superfamily receptors and their use in treatment of disease |
US8389510B2 (en) * | 2005-11-18 | 2013-03-05 | Astrazeneca Ab | Crystalline forms |
CN101360724A (zh) * | 2005-11-18 | 2009-02-04 | 阿斯利康公司 | 盐形式 |
WO2007062337A2 (en) * | 2005-11-18 | 2007-05-31 | Astrazeneca Ab | Crystalline forms |
US20090069292A1 (en) * | 2005-11-18 | 2009-03-12 | Astrazeneca Ab | Liquid Formulations |
CN101360725B (zh) * | 2005-11-18 | 2011-09-21 | 阿斯利康公司 | 固体制剂 |
WO2007100937A2 (en) * | 2006-01-19 | 2007-09-07 | The Regents Of The University Of Michigan | System and method for spectroscopic photoacoustic tomography |
US9012605B2 (en) | 2006-01-23 | 2015-04-21 | Amgen Inc. | Crystalline polypeptides |
WO2008063639A2 (en) * | 2006-11-21 | 2008-05-29 | Massachusetts Eye And Ear Infirmary | Compositions and methods for preserving cells of the eye |
US20080123083A1 (en) * | 2006-11-29 | 2008-05-29 | The Regents Of The University Of Michigan | System and Method for Photoacoustic Guided Diffuse Optical Imaging |
WO2009018429A2 (en) * | 2007-07-31 | 2009-02-05 | The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healt Of Human Services, National Institutes Of Healt | TREATMENT OF CANCER VIA TARGETING OF IL-13 RECEPTOR-α2 |
CA2715080C (en) | 2007-09-28 | 2021-09-28 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
AU2009210741A1 (en) * | 2008-02-07 | 2009-08-13 | Amgen Inc. | Stabilized protein compositions |
CN101591388A (zh) * | 2008-05-30 | 2009-12-02 | 上海复旦张江生物医药股份有限公司 | 一种可溶性tnf受体突变体 |
TR201903546T4 (tr) | 2009-07-28 | 2019-04-22 | Ge Healthcare Bio Sciences Corp | Aşı stabilizatörü. |
CN109157742B (zh) | 2009-08-03 | 2022-04-05 | 因卡伯实验室有限责任公司 | 用于刺激肠道内肠促胰岛素产生的吞咽式囊和方法 |
EP2494352B1 (en) * | 2009-10-26 | 2020-04-08 | Prometheus Biosciences, Inc. | Assays for the detection of anti-tnf drugs and autoantibodies |
JP2013512674A (ja) * | 2009-12-02 | 2013-04-18 | アクセルロン ファーマ, インコーポレイテッド | Fc融合タンパク質の血清半減期を増加させるための組成物および方法 |
US8721620B2 (en) | 2009-12-24 | 2014-05-13 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
WO2011141926A2 (en) * | 2010-05-10 | 2011-11-17 | Intas Biopharmaceuticals Limited | Liquid formulation of polypeptides containing an fc domain of an immunoglobulin |
SG189391A1 (en) | 2010-10-18 | 2013-05-31 | Nestec Sa | Methods for determining anti-drug antibody isotypes |
US8809271B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising liraglutide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402807B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9259386B2 (en) | 2010-12-23 | 2016-02-16 | Rani Therapeutics, Llc | Therapeutic preparation comprising somatostatin or somatostatin analogoue for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9861683B2 (en) | 2010-12-23 | 2018-01-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8734429B2 (en) | 2010-12-23 | 2014-05-27 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US9415004B2 (en) | 2010-12-23 | 2016-08-16 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US10639272B2 (en) | 2010-12-23 | 2020-05-05 | Rani Therapeutics, Llc | Methods for delivering etanercept preparations into a lumen of the intestinal tract using a swallowable drug delivery device |
US8846040B2 (en) | 2010-12-23 | 2014-09-30 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising etanercept for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9629799B2 (en) | 2010-12-23 | 2017-04-25 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9283179B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | GnRH preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9402806B2 (en) | 2010-12-23 | 2016-08-02 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8980822B2 (en) | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US9284367B2 (en) | 2010-12-23 | 2016-03-15 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8809269B2 (en) | 2010-12-23 | 2014-08-19 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising insulin for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US8969293B2 (en) | 2010-12-23 | 2015-03-03 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising exenatide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US20130330340A1 (en) * | 2011-02-25 | 2013-12-12 | Stephen R. Hamilton | Production of n- and o-sialylated tnfrii-fc fusion protein in yeast |
AU2012244764B2 (en) * | 2011-04-20 | 2016-10-13 | Sandoz Ag | Stable pharmaceutical liquid formulations of the fusion protein TNFR:Fc |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
EP2718328A4 (en) | 2011-06-08 | 2014-12-24 | Acceleron Pharma Inc | COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM |
EA026226B1 (ru) * | 2011-07-01 | 2017-03-31 | Байоджен Айдек Ма Инк. | Не содержащие аргинина композиции слитого fc-полипептида и способы их применения |
RU2013158256A (ru) | 2011-07-06 | 2015-07-10 | Нестек С.А. | АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα |
SG11201401562RA (en) | 2011-10-18 | 2014-09-26 | Coherus Biosciences Inc | Etanercept formulations stabilized with sodium chloride |
US10485869B2 (en) | 2011-10-18 | 2019-11-26 | Coherus Biosciences, Inc. | Etanercept formulations stabilized with meglumine |
CN104661651A (zh) * | 2012-07-09 | 2015-05-27 | 科荣生生物科学公司 | 表现出不溶性微粒显著减少的依那西普制剂 |
ES2657377T3 (es) | 2012-09-11 | 2018-03-05 | Coherus Biosciences, Inc. | Etanercept plegado correctamente con alta pureza y excelente rendimiento |
KR20150093695A (ko) | 2012-11-09 | 2015-08-18 | 코넬 유니버시티 | Malt1의 소분자 억제제 |
WO2014078627A1 (en) | 2012-11-19 | 2014-05-22 | Merck Sharp & Dohme Corp. | Liquid formulations for tnfr:fc fusion proteins |
CN104870019A (zh) * | 2012-11-27 | 2015-08-26 | 阿特根公司 | 用于稳定蛋白质和Fc结构域融合的融合蛋白的组合物 |
CA2930227C (en) * | 2013-11-29 | 2021-09-28 | Ares Trading S.A. | A liquid formulation of a fusion protein comprising tnfr and fc region |
EP2975050B1 (en) * | 2014-07-18 | 2019-05-29 | Sandoz Ag | Quantification of misfolded TNFR2:Fc |
US9775978B2 (en) | 2014-07-25 | 2017-10-03 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a retaining member |
US10080877B2 (en) | 2014-07-25 | 2018-09-25 | Warsaw Orthopedic, Inc. | Drug delivery device and methods having a drug cartridge |
US9821059B2 (en) | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
EP3017825A1 (en) * | 2014-11-06 | 2016-05-11 | Ludwig-Maximilians-Universität München | An inhibitor of the RIPK1-dependent necrosis pathway and a pharmaceutical composition comprising the same |
TW201628644A (zh) * | 2014-11-25 | 2016-08-16 | 奈諾生技公司 | 醫藥組合物、其製備及其用途 |
EP3227683B1 (en) | 2014-12-05 | 2019-04-24 | Nestec S.A. | Indirect homogeneous mobility shift assays for the detection of biologics in patient samples |
WO2016100232A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 |
CA2971186A1 (en) | 2014-12-15 | 2016-06-23 | The Regents Of The University Of California | Cytotoxic molecules responsive to intracellular ligands for selective t cell mediated killing |
EP3236990B1 (en) | 2014-12-22 | 2020-09-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
CN105636937B (zh) * | 2015-01-27 | 2018-07-17 | 深圳华大生命科学研究院 | 用于保存生物样品的稳定剂 |
EP3265107B1 (en) | 2015-03-02 | 2024-10-02 | 180 Therapeutics LP | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist |
US10076650B2 (en) | 2015-11-23 | 2018-09-18 | Warsaw Orthopedic, Inc. | Enhanced stylet for drug depot injector |
USD802757S1 (en) | 2016-06-23 | 2017-11-14 | Warsaw Orthopedic, Inc. | Drug pellet cartridge |
CN109963590B (zh) | 2016-09-02 | 2024-03-15 | 加利福尼亚大学董事会 | 涉及白介素-6受体α结合单链可变片段的方法和组合物 |
EP3518971A4 (en) * | 2016-09-28 | 2020-05-13 | Board Of Regents, The University Of Texas System | ANTIBODIES AND THERAPEUTIC PROTEIN FORMULATIONS AND USES THEREOF |
KR20180046888A (ko) | 2016-10-28 | 2018-05-09 | (주)셀트리온 | 안정한 약제학적 제제 |
US10434261B2 (en) | 2016-11-08 | 2019-10-08 | Warsaw Orthopedic, Inc. | Drug pellet delivery system and method |
WO2020003139A2 (en) * | 2018-06-26 | 2020-01-02 | Lupin Limited | Stable lyophilized dosage form of protein |
CN112805014A (zh) | 2018-07-03 | 2021-05-14 | 芬内克制药股份有限公司 | 无水硫代硫酸钠的调配物 |
CN111408343B (zh) * | 2019-01-08 | 2022-01-28 | 湖南农业大学 | 三维立体生物炭的制备方法及其在重金属吸附中的应用 |
CN110433172B (zh) * | 2019-07-10 | 2022-04-08 | 郴州市第一人民医院 | 一种具有治疗非小细胞肺癌功效的药物及其用途 |
JP2024503239A (ja) | 2020-12-22 | 2024-01-25 | アムジェン インコーポレイテッド | 細胞培養法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5945397A (en) * | 1989-09-05 | 1999-08-31 | Immunex Corporation | Purified p75 (type II) tumor necrosis factor receptor polypeptides |
KR100923514B1 (ko) * | 2000-12-28 | 2009-10-27 | 알투스 파마슈티컬스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
-
2004
- 2004-07-29 BR BRPI0413197-5A patent/BRPI0413197A/pt not_active Application Discontinuation
- 2004-07-29 CA CA002533796A patent/CA2533796A1/en not_active Abandoned
- 2004-07-29 KR KR1020067001733A patent/KR20070008501A/ko not_active Application Discontinuation
- 2004-07-29 SG SG200805780-4A patent/SG145712A1/en unknown
- 2004-07-29 US US10/901,735 patent/US7276477B2/en active Active
- 2004-07-29 CN CNB2004800214984A patent/CN100509847C/zh not_active Expired - Fee Related
- 2004-07-29 RU RU2006101216/04A patent/RU2006101216A/ru unknown
- 2004-07-29 WO PCT/US2004/024738 patent/WO2005012353A1/en active Application Filing
- 2004-07-29 JP JP2006522109A patent/JP2007521315A/ja active Pending
- 2004-07-29 EP EP04779710A patent/EP1654281A1/en not_active Ceased
- 2004-07-29 NZ NZ545221A patent/NZ545221A/en unknown
- 2004-07-29 AU AU2004262014A patent/AU2004262014B2/en not_active Ceased
- 2004-08-02 TW TW093123111A patent/TWI291468B/zh not_active IP Right Cessation
-
2006
- 2006-01-09 NO NO20060128A patent/NO20060128L/no not_active Application Discontinuation
- 2006-01-20 EC EC2006006299A patent/ECSP066299A/es unknown
- 2006-01-29 IL IL173413A patent/IL173413A0/en unknown
- 2006-01-31 ZA ZA200600909A patent/ZA200600909B/en unknown
- 2006-02-01 CR CR8224A patent/CR8224A/es not_active Application Discontinuation
-
2007
- 2007-01-19 HK HK07100718.4A patent/HK1093749A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW200510453A (en) | 2005-03-16 |
ECSP066299A (es) | 2006-07-28 |
SG145712A1 (en) | 2008-09-29 |
EP1654281A1 (en) | 2006-05-10 |
NZ545221A (en) | 2009-09-25 |
WO2005012353A1 (en) | 2005-02-10 |
TWI291468B (en) | 2007-12-21 |
NO20060128L (no) | 2006-04-06 |
CN1829739A (zh) | 2006-09-06 |
KR20070008501A (ko) | 2007-01-17 |
CA2533796A1 (en) | 2005-02-10 |
AU2004262014A1 (en) | 2005-02-10 |
HK1093749A1 (en) | 2007-03-09 |
JP2007521315A (ja) | 2007-08-02 |
IL173413A0 (en) | 2006-06-11 |
BRPI0413197A (pt) | 2006-10-03 |
AU2004262014B2 (en) | 2010-06-17 |
CN100509847C (zh) | 2009-07-08 |
ZA200600909B (en) | 2007-05-30 |
US7276477B2 (en) | 2007-10-02 |
RU2006101216A (ru) | 2007-07-20 |
US20050032183A1 (en) | 2005-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8224A (es) | Polipepticos cristalinos del receptor 2 del factor de necrosis de tumor | |
ATE461217T1 (de) | Glp-1-verbindungen | |
DK1581300T3 (da) | Væskeapplikator med mekanisme til brydning af flere ampuller | |
ATE445402T1 (de) | Neue verwendung von pde5-hemmern | |
ECSP077401A (es) | Medicamentos que contienen compuestos de carbonilo y su uso | |
DE502004006863D1 (de) | Synthese von phenylsubstituierten fluoranthenen durch diels-alder-reaktion und ihre verwendung | |
ES2570772T3 (es) | Dispositivos polarizantes y procedimientos de fabricación de los mismos | |
CY1113721T1 (el) | Πολυσταθης ανακλαστικη διαταξη υγρων κρυσταλλων | |
DE60321906D1 (de) | Management des stimulationserfolgs bei mehrkammerstimulation | |
ECSP045474A (es) | 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6 | |
UY28258A1 (es) | Tratamiento terapeutico | |
NO20061122L (no) | 2-(Quinoksalin-5-ylsuflonylamino)-benzamid forbindelser som CCK2 modulatorer | |
CL2009001214A1 (es) | Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos | |
CR7583A (es) | Nueva sal formiato de o-desmetil venlafaxina | |
HN2004000319A (es) | "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia" | |
DK1899334T3 (da) | Naphthyridinforbindelser | |
CR7042A (es) | Indanil aminas aciladas y su uso como farmacos | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
ATE496892T1 (de) | Tetrahydroisochinolinverbindungen zur behandlung von zns-erkrankungen | |
ATE407466T1 (de) | Schleifringbürste und damit ausgestattete schleifringeinheit | |
NO20093542L (no) | Inhibering av tumormetastase ved hjelp av anti-neuropilin 2-antistoffer | |
ECSP088468A (es) | Moduladores de canabinoide de 5-heteroaril-1-fenil-pirazol sustituido | |
UY29774A1 (es) | Inhibidor de atm | |
UY28344A1 (es) | Nuevos compuestos | |
DE60323645D1 (de) | Duschvorrichtung mit bräunungsvorrichtung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |